307 related articles for article (PubMed ID: 16100297)
1. Effect of exenatide on the steady-state pharmacokinetics of digoxin.
Kothare PA; Soon DK; Linnebjerg H; Park S; Chan C; Yeo A; Lim M; Mace KF; Wise SD
J Clin Pharmacol; 2005 Sep; 45(9):1032-7. PubMed ID: 16100297
[TBL] [Abstract][Full Text] [Related]
2. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
Cohen E; Almog S; Staruvin D; Garty M
Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
[TBL] [Abstract][Full Text] [Related]
3. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
4. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
5. Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma.
Hashimoto Y; Shibakawa K; Nakade S; Miyata Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):126-32. PubMed ID: 18515196
[TBL] [Abstract][Full Text] [Related]
6. The serum digoxin concentration: ten questions to ask.
Cauffield JS; Gums JG; Grauer K
Am Fam Physician; 1997 Aug; 56(2):495-503, 509-10. PubMed ID: 9262530
[TBL] [Abstract][Full Text] [Related]
7. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
[TBL] [Abstract][Full Text] [Related]
8. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin.
Toothaker RD; Corey AE; Valentine SN; Agnew JR; Parekh N; Moehrke W; Thompson GA; Powell JH
J Clin Pharmacol; 2005 Jul; 45(7):773-80. PubMed ID: 15951467
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction of sparfloxacin and digoxin.
Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers.
Chaufour S; Le Coz F; Denolle T; Dubruc C; Cimarosti I; Deschamps C; Ulliac N; Delhotal-Landes B; Rosenzweig P
Int J Clin Pharmacol Ther; 1998 May; 36(5):286-91. PubMed ID: 9629994
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
Blase E; Taylor K; Gao HY; Wintle M; Fineman M
J Clin Pharmacol; 2005 May; 45(5):570-7. PubMed ID: 15831781
[TBL] [Abstract][Full Text] [Related]
13. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers.
Stangier J; Su CA; Hendriks MG; van Lier JJ; Sollie FA; Oosterhuis B; Jonkman JH
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1373-9. PubMed ID: 11185636
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
15. Absence of a clinically relevant interaction between etanercept and digoxin.
Zhou H; Parks V; Patat A; Le Coz F; Simcoe D; Korth-Bradley J
J Clin Pharmacol; 2004 Nov; 44(11):1244-51. PubMed ID: 15496642
[TBL] [Abstract][Full Text] [Related]
16. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin.
Di Cicco RA; Miller AK; Patterson S; Freed MI
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1516-21. PubMed ID: 11185675
[TBL] [Abstract][Full Text] [Related]
18. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
[TBL] [Abstract][Full Text] [Related]
19. Effect of troglitazone on steady-state pharmacokinetics of digoxin.
Loi CM; Knowlton PW; Stern R; Randinitis EJ; Vassos AB; Koup JR; Sedman AJ
J Clin Pharmacol; 1998 Feb; 38(2):178-83. PubMed ID: 9549650
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole does not affect the steady-state pharmacokinetics of digoxin.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):45-50. PubMed ID: 14616413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
